Deal Watch: AbbVie Cancels Shire Buyout, Blaming U.S. Tax Policy Revisions
Executive Summary
Actavis potentially bolsters its GI franchise by optioning rights to peptide ghrelin agonist relamorelin and also the opportunity to buy out Rhythm Health. Meanwhile, Celgene increases its stake in Sutro and Janssen joins the Ebola fight.
You may also be interested in...
Death And Tax Inversion: Policy Fight Won't Go Away, Now Spawning Lawsuits
US Chamber of Commerce wants court to eliminate IRS rule that blocked Pfizer's acquisition of Allergan; AbbVie hit with second suit over its 2014 proposed acquisition of Shire.
Celgene Dips Into The Antibody Well Once More, Partners With Sutro
Celgene Corp. has deepened its investment in antibody R&D, striking a collaboration with Sutro Biopharma to design and develop next-gen antibodies and to manufacture a proprietary Celgene candidate. Sutro gets cash, biobucks, and hi-profile validation of its multi-faceted non-cell antibody platform.
Indivior Reorganizing And Re-Investing In US Commercial Functions
Indivior aims to cut costs by restructuring its US commercial operations and reducing discretionary spending, in order to improve flexibility in the face of the COVID-19 pandemic and to invest in R&D.
Need a specific report? 1000+ reports available Buy Reports
Register for our free email digests: